Boston Scientific Faces Class Action Lawsuit Over Misleading Growth Projections

2026-03-25 companies

Marlborough, Wednesday, 25 March 2026.
Boston Scientific faces a class action lawsuit for allegedly hiding unsustainable growth rates, a revelation that previously triggered a massive 17.6% stock drop and erased significant investor value.

Unpacking the Electrophysiology Growth Discrepancy

Multiple prominent law firms, including Robbins Geller Rudman & Dowd LLP and Levi & Korsinsky, LLP, have launched class action lawsuits against medical device manufacturer Boston Scientific Corporation (NYSE: BSX) [1][2]. The litigation, which encompasses a Class Period spanning from July 23, 2025, to February 3, 2026, centers on the company’s United States Electrophysiology (EP) business segment [1][2]. According to the complaints, Boston Scientific presented a misleadingly optimistic revenue outlook while minimizing competitive risks [1]. Management allegedly assured investors that they had a firm grasp on the competitive landscape and projected that the EP market would sustain a 15% long-range growth rate, driven significantly by its FARAPULSE platform [2][3].

The Catalyst for the Crash

The narrative unraveled on February 4, 2026, when Boston Scientific released its financial results for the fourth quarter and full year of 2025 [1]. On paper, the company demonstrated profitability, reporting a fourth-quarter GAAP net income attributable to common stockholders of $672 million, or $0.45 per share, an increase from the $566 million, or $0.38 per share, recorded in the prior year [1]. For the full year 2025, GAAP net income reached $2.898 billion, or $1.94 per share, compared to $1.853 billion, or $1.25 per share, in 2024 [1]. This translates to a year-over-year full-year net income growth of 56.395 percent [1]. However, beneath the surface of these earnings, the company issued a corrective disclosure attributing disappointing U.S. EP sales and a revised fiscal year 2026 guidance to slower-than-expected market growth and intensified competition [2][3].

Current Market Sentiment and Next Steps for Shareholders

In the weeks following the crash, investor sentiment has remained decidedly cautious. As of March 23, 2026, Boston Scientific’s stock exhibited a muted 0.09% daily gain, while trading volume plunged by 46.03% to $0.76 billion [5]. This sharp contraction in trading activity suggests that market participants are adopting a wait-and-see approach, seeking further clarity on the company’s operational footing and the potential financial impact of the mounting legal challenges [5]. The U.S. EP segment remains a critical revenue driver for the medical device giant, and any prolonged disruption could significantly alter its long-term valuation [5].

Sources

Shareholder litigation Class action